Windyga Jerzy, Grabarczyk Piotr, Stefańska Ewa, Buczma Anna, Szczepanik Andrzej Bogusław, Klukowska Anna, Mikulska Maria, Medyńska Joanna, Brojer Ewa
Klinika Zaburzeń Hemostazy i Chorób Wewnetrznych.
Przegl Epidemiol. 2008;62(2):415-23.
In the past, haemophilia replacement therapy was based on fresh frozen plasma, cryoprecipitate and blood transfusions--i.e. preparates not subjected to any viral inactivation methods. The aim of the present study was to assess the prevalence of HCV, HBV and HIV infections among Polish haemophiliacs.
Severe haemophilia patients were divided into two age groups according to the type of replacement therapy used in the past: group 1--172 patients born 1935-1990, group 2--41 patients born 1991-2002. The following viral markers were tested: anti-HCV, RNA HCV (if needed--virus genotype), HBsAg and anti-HIV. In 75 patients / group 1 and 41 / group 2, anti-HBc presence was determined.
In group 1, 95% of patients were anti-HCV positive and in 77.3% RNA HCV was detected. The most prevalent was lb genotype (58.6%) followed by 3a (27%). HBsAg was found in 8.7% cases of group 1. Anti-HCV antibodies were detected in 51 of 75 (68%) patients of this group. One patient was anti-HIV positive. In only one patient of group 2 (2.4%) viral markers were detected (anti-HCV and RNA HCV).
Nowadays, the risk of HCV, HBV and HIV infection in Polish severe haemophiliacs is very low.
过去，血友病替代疗法基于新鲜冷冻血浆、冷沉淀和输血——即未经过任何病毒灭活方法处理的制剂。本研究的目的是评估波兰血友病患者中丙型肝炎病毒（HCV）、乙型肝炎病毒（HBV）和人类免疫缺陷病毒（HIV）感染的患病率。
根据过去使用的替代疗法类型，将重度血友病患者分为两个年龄组：第1组——172例出生于1935年至1990年的患者，第2组——41例出生于1991年至2002年的患者。检测以下病毒标志物：抗HCV、HCV RNA（如有需要——病毒基因型）、HBsAg和抗HIV。在第1组的75例患者和第2组的41例患者中，测定了抗HBc的存在情况。
在第1组中，95%的患者抗HCV呈阳性，77.3%的患者检测到HCV RNA。最常见的是1b基因型（58.6%），其次是3a基因型（27%）。在第1组的8.7%的病例中发现了HBsAg。在该组75例患者中的51例（68%）检测到抗HCV抗体。1例患者抗HIV呈阳性。在第2组中，仅1例患者（2.4%）检测到病毒标志物（抗HCV和HCV RNA）。
如今，波兰重度血友病患者感染HCV、HBV和HIV的风险非常低。
